Zekun K. Li

Beijing Key Laboratory Of Pediatric Hematology Oncology National Key Discipline Of Pediatrics Key Laboratory Of Major Diseases In Children
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Emicizumab prophylaxis vs immune tolerance induction in children with severe hemophilia A and inhibitors: a retrospective comparison of bleeding control, quality of life, and cost.

Emicizumab prophylaxis vs immune tolerance induction in children with severe hemophilia A and inhibitors: a retrospective comparison of bleeding control, quality of life, and cost.

Journal: Research and practice in thrombosis and haemostasis

Published: December 20, 2025

Machine learning estimation of FVIII pharmacokinetic parameters in Chinese children with severe Hemophilia A.

Machine learning estimation of FVIII pharmacokinetic parameters in Chinese children with severe Hemophilia A.

Journal: NPJ systems biology and applications

Published: September 25, 2025

Assessment of Deep Water-Saving Practice Effects on Crop Coefficients and Water Consumption Processes in Cultivated Land-Wasteland-Lake Systems of the Hetao Irrigation District.

Assessment of Deep Water-Saving Practice Effects on Crop Coefficients and Water Consumption Processes in Cultivated Land-Wasteland-Lake Systems of the Hetao Irrigation District.

Journal: Plants (Basel, Switzerland)

Published: August 07, 2025

Significant PK variability of plasma-derived FIX concentrates in chinese children with Haemophilia B: A fixed single-dose study of factor IX-CTBB.

Significant PK variability of plasma-derived FIX concentrates in chinese children with Haemophilia B: A fixed single-dose study of factor IX-CTBB.

Journal: Global medical genetics

Published: January 09, 2025

Single-cell sequencing on PBMCs from patients with HA and HB with inhibitors reveals different immune responses to FVIII and FIX.

Single-cell sequencing on PBMCs from patients with HA and HB with inhibitors reveals different immune responses to FVIII and FIX.

Journal: Blood advances

Published: January 02, 2025

A comparison of My Precise Dose and WAPPS-Hemo as dosing tools for optimizing prophylaxis in children with hemophilia A treated with BAY 81-8973.

A comparison of My Precise Dose and WAPPS-Hemo as dosing tools for optimizing prophylaxis in children with hemophilia A treated with BAY 81-8973.

Journal: Thrombosis research

Published: December 25, 2024

Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing.

Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing.

Journal: Journal of thrombosis and haemostasis : JTH

Published: November 16, 2024

Nanoparticle delivery systems of functional substances for precision nutrition.

Nanoparticle delivery systems of functional substances for precision nutrition.

Journal: Advances in food and nutrition research

Published: September 01, 2024

Differential genes expression of immune tolerance induction in hemophilia A: an exploratory RNA-seq test from a Chinese hemophilia comprehensive care centre.

Differential genes expression of immune tolerance induction in hemophilia A: an exploratory RNA-seq test from a Chinese hemophilia comprehensive care centre.

Journal: Translational pediatrics

Published: August 02, 2024

Long-term health-related quality of life and related factors in children with severe hemophilia A who received regular low-dose prophylaxiss

Long-term health-related quality of life and related factors in children with severe hemophilia A who received regular low-dose prophylaxiss

Journal: Zhonghua yi xue za zhi

Published: July 30, 2024

Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial.

Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial.

Journal: Research and practice in thrombosis and haemostasis

Published: July 21, 2024

Low-dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor-titer below 200 BU/mL.

Low-dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor-titer below 200 BU/mL.

Journal: Pediatric investigation

Published: February 13, 2024

Showing 1-12 of 38

Last Updated: 09/26/2026